R Squared’s Q32 Bio QTTB Stock Holding History

R Squared’s Portfolio QTTB Stock Details QTTB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-750	Closed	-$2.58K	–	1556
2024 Q4	$2.58K	Buy	+750	New	+$23.7K	﹤0.01%	1434

Other funds holding QTTB

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

R Squared's QTTB Position: Q1 2025 in Review

R Squared sold out of Q32 Bio (QTTB) in Q1 2025, closing a stake of 750 shares — an estimated $2.58K sold.

R Squared first reported a position in QTTB in Q4 2024 and held it in 1 quarter. The position peaked at $2.58K in Q4 2024. 73 funds tracked by Wall St. Rank hold QTTB as of Q1 2025.

R Squared reported no remaining Q32 Bio position as of Q1 2025 after selling out during the quarter.
R Squared sold 750 Q32 Bio shares in Q1 2025, an estimated $2.58K.
R Squared first reported a position in Q32 Bio in Q4 2024 and held it in 1 quarter.
R Squared's Q32 Bio position peaked at $2.58K in Q4 2024.
73 funds tracked by Wall St. Rank held Q32 Bio as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.